August 2026– date –
-
Rice University Engineers Harness Electrostatic Charge for Weeks-Long Controlled Peptide Release, Revolutionizing Regenerative Medicine
Rice University USA Overview Engineers at Rice University have developed a novel strategy to precisely control the release of therapeutic peptides from gelatin-based materials. By adjusting the peptide's electrical charge, the team signi... -
Beijing Designates Xtalpi and Gan & Lee’s AI Peptide Delivery Lab as Key National Facility for Oral Drug Innovation
Insight, China's Pharmaceutical Industry China Overview The AI Peptide Delivery Lab, a joint venture by Xtalpi and Gan & Lee Pharmaceuticals, has been officially designated a Beijing Key Laboratory, recognizing its cutting-edge R&... -
Fatal Adverse Event Halts HuidaGene’s First-in-Human CRISPR Gene Therapy Trial for DMD
HuidaGene Therapeutics China Overview HuidaGene Therapeutics has reported a fatal serious adverse event (SAE) in the HG302-01 first-in-human trial of its investigational CRISPR-based gene-editing therapy, HG302, for Duchenne muscular dys... -
Peptide Therapeutics: Charting a Course to Oral Delivery Amidst a Surge in FDA Approvals
Stanford Medicine USA Overview The FDA has approved nearly 100 peptide therapeutics for conditions ranging from diabetes to multiple sclerosis, yet most require injection due to their susceptibility to gastrointestinal degradation. A rec... -
Lonza Capsugel Pioneers Dual-Layer Strategy for Oral GLP-1 Delivery, Shielding Peptides from Enzymatic Attack
Capsugel (Lonza) Switzerland Overview Lonza Capsugel has engineered a novel dual-layer protection strategy to enable oral delivery of GLP-1 peptides, circumventing the critical challenge of enzymatic degradation within the gastrointestin... -
Alector Advances ‘Brain Carrier’ Platform: Optimizing Brain Drug Delivery via Transferrin Receptor Targeting with Enhanced Safety
Alector USA Overview Alector recently announced significant progress with its proprietary Alector Brain Carrier (ABC) blood-brain barrier (BBB) platform, designed to substantially enhance the delivery of therapeutic agents to the brain. ... -
FDA Grants Dual Breakthrough and Orphan Designations to Volixibat for PSC-Related Cholestatic Pruritus
HCPLive USA Overview The U.S. FDA has granted both Breakthrough Therapy Designation (BTD) and Orphan Drug Designation (ODD) to volixibat, an investigational ileal bile acid transporter (IBAT) inhibitor, for the treatment of cholestatic p... -
ReCode Therapeutics Secures Funding, Partners with Gene Editing Firm to Fast-Track Cystic Fibrosis Gene Therapy with SORT LNP Platform
BioSpace (via Business Wire) USA Overview ReCode Therapeutics has announced new funding from the Cystic Fibrosis Foundation and a strategic partnership with a leading gene editing company. These initiatives will accelerate the developmen... -
Eurofins CDMO Alphora Expands Kilolab and HPAPI Manufacturing, Strengthening Integrated ADC Development
Las Vegas Sun News (via Business Wire) USA Overview Eurofins CDMO Alphora has significantly expanded its kilolab and High Potency Active Pharmaceutical Ingredient (HPAPI) development and manufacturing capabilities at its Mississauga, Can... -
Monte Rosa’s AI-Powered Molecular Glue Degrader MRT-6160 Achieves >90% VAV1 Degradation and Potent Cytokine Suppression in Phase 1, Prompting Multiple Novartis-Led Phase 2 Trials
Quartr Sweden Overview Monte Rosa Therapeutics has announced that its AI-driven QuEEN platform's molecular glue degrader (MGD) MRT-6160 achieved over 90% VAV1 protein degradation and potent cytokine suppression in Phase 1 trials. This su...
